Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. (Q50922149)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 August 2012

Language	Label	Description	Also known as
English	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.	scientific article published on 2 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

1 reference

based on heuristic

inferred from title

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

toxic encephalopathy

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

12

object named as

H P Kalofonos

0 references

author name string

A A Argyriou

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

R Velasco

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

C Briani

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

G Cavaletti

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

M Cacciavillani

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

C Santos

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

D Cortinovis

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

M Cazzaniga

11

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

H P Kalofonos

12

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

publication date

2 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

23

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

12

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

3116-3122

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Adjuvant therapy in colon cancer--what, when and how?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

A review on oxaliplatin-induced peripheral nerve damage.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

A review of oxaliplatin and its clinical use in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Oxaliplatin-related neurotoxicity: how and why?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Chemotherapy-induced peripheral neurotoxicity (CIPN): an update

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Peripheral neuropathy associated with capecitabine.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS208

21 January 2018

Identifiers

10.1093/ANNONC/MDS208

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22865779

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50922149&oldid=1588118960"